These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 29764589)

  • 21. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
    Dong Y; Zhou Z; Wang J; Ma L; Liu Z; Wang Y; Song J; Zhang S; Che N
    Pathol Res Pract; 2019 May; 215(5):946-951. PubMed ID: 30760406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.
    Taus Á; Camacho L; Rocha P; Hardy-Werbin M; Pijuan L; Piquer G; López E; Dalmases A; Longarón R; Clavé S; Salido M; Albanell J; Bellosillo B; Arriola E
    Clin Lung Cancer; 2018 Sep; 19(5):387-394.e2. PubMed ID: 29656868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
    Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
    Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma.
    Cui S; Ye L; Wang H; Chu T; Zhao Y; Gu A; Xiong L; Shi C; Jiang L
    Clin Lung Cancer; 2018 May; 19(3):e313-e322. PubMed ID: 29329944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
    Zhang C; Wei B; Li P; Yang K; Wang Z; Ma J; Guo Y
    PLoS One; 2017; 12(3):e0173524. PubMed ID: 28333951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
    Buder A; Setinek U; Hochmair MJ; Schwab S; Kirchbacher K; Keck A; Burghuber OC; Pirker R; Filipits M
    Target Oncol; 2019 Apr; 14(2):197-203. PubMed ID: 30810887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center.
    Assi H; Tfayli A; Assaf N; Daya SA; Bidikian AH; Kawsarani D; Fermanian P; Zaatari G; Mahfouz R
    Mol Biol Rep; 2019 Aug; 46(4):3671-3676. PubMed ID: 31147859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
    Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
    JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma.
    Isobe K; Hata Y; Tochigi N; Kaburaki K; Kobayashi H; Makino T; Otsuka H; Ishida F; Hirota N; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Iyoda A; Homma S
    Cancer Genomics Proteomics; 2015; 12(1):31-7. PubMed ID: 25560642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
    Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
    Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
    Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
    Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
    Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
    BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
    Lee YJ; Yoon KA; Han JY; Kim HT; Yun T; Lee GK; Kim HY; Lee JS
    Clin Cancer Res; 2011 Aug; 17(15):5179-87. PubMed ID: 21653691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.